IRF8 and neoplasm: In ER+ tumor samples, the presence of IRF8 appears to have no effect in discriminating the patient outcome, indicating that in this subgroup of patients, which bear mostly grade 1–2 tumors, there are other features or factors that are leading the tumor growth and that could act as better prognostic factors.